Nightingale Health Plc
Press release
20 August 2024 at 9:45 a.m. (EEST)
Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, has attained UKCA (UK Conformity Assessed) marking under the UK Medical Devices Regulations.
Nightingale Health has already been working for years with many leading universities in the UK and the technology is being used by many landmark health initiatives, such as the UK Biobank, to profile their entire sample collections.
To expand its activities in the UK, Nightingale Health has established a local laboratory in Porton Science Park in South Wiltshire. By having its proprietary blood analysis technology locally available in the UK, Nightingale Health aims to expand its partnerships within the entire health ecosystem in the country.
The UKCA marking shows compliance with the UK requirements for medical devices and is an important step in bringing Nightingale Health’s blood analysis technology to healthcare use in the UK.
“Nightingale Health’s blood analysis technology demonstrates again its capabilities to become the new improved standard in routine blood testing for chronic diseases. By replacing the current methods of clinical chemistry, Nightingale Health’s blood test can offer groundbreaking value in building more preventative and sustainable healthcare,” says Teemu Suna, Nightingale Health’s CEO and Founder.
“Our technology not only replaces directly many of the common blood values, but importantly offers additionally, for the first time in the diagnostic industry, a possibility to detect comprehensively the risk for developing chronic diseases. These capabilities are enabled by the unique combination of Nightingale Health’s proprietary blood analysis technology and pioneering population data driven approach,” Suna continues.
“Nightingale Health’s technology is already used in nationwide primary healthcare in Finland covering approximately 30% of Finland’s working population. In addition to the UK, we are also making rapid progress in the United States and in Singapore in adopting our technology in healthcare. We are truly excited to bring the advantages of modern blood testing technology available around the world, and the UKCA marking in the UK continues to demonstrate the high quality and performance of our unique technology” Suna concludes.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Tags: